Physician profile
Thomas B Morrison
NPI 1104021583
$1,188.43
in general payments reported to CMS, 2019-2025
15 companies · $99.49 in 2025
The $99.49 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $66.32 · 2021: $273 · 2022: $274 · 2023: $73.04 · 2024: $207 · 2025: $99.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $305.15 | 2019-2024 | Mitraclip |
| Edwards Lifesciences Corporation | $161.84 | 2021-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novartis Pharmaceuticals Corporation | $155.64 | 2019-2025 | |
| Abiomed | $118.69 | 2024 | Impella |
| Medtronic, INC. | $95.12 | 2022 | |
| Janssen Pharmaceuticals, INC | $87.26 | 2020-2023 | Xarelto |
| Amgen INC. | $79.91 | 2020-2025 | Repatha, Repatha |
| Pfizer INC. | $44.91 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.50 | 2025 | Lifevest |
| Biosense Webster, INC. | $27.24 | 2024 | Carto 3 |
| Braemar Manufacturing, LLC | $21.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.34 | 2024 | |
| Merck Sharp & Dohme LLC | $14.72 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.87 | 2025 | Opsynvi, Uptravi |
| Esperion Therapeutics, INC. | $13.74 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.